News about "Schizophrenia treatment"

Teva Wins US FDA Approval for Monthly Olanzapine Injection

Teva has announced US FDA approval of WELTRUZA for ER injectable suspension, as the first and only once-monthly subcutaneous injectable polanzapine for adults.

Schizophrenia Treatment | 12/10/2026 | By News Bureau

Teva Plans Acquisition of Novel Neuroscience Product

Teva plans to acquire BXCL501, a novel dexmedetomidine sublingual film under the US Food and Drug Administration (FDA) review for potential at-home treatment of acute agitation in adults with schizophrenia or bipolar disorder.

Schizophrenia Treatment | 01/09/2026 | By News Bureau

TG Therapeutics Launches Phase 2 Trial of BRIUMVI for Schizophrenia

TG Therapeutics has initiated a Phase 2 trial of BRIUMVI in treatment-resistant schizophrenia, evaluating B-cell depletion as a potential therapy for patients with immune dysfunction.

Schizophrenia Treatment | 07/07/2026 | By News Bureau |  191

Newron Provides Update Following Type A Meeting with the US FDA

Newron has provided an update following its Type A meeting with the US Food and Drug Administration (FDA), outlining the steps required to resume US enrollment in the phase 3 ENIGMA-TRS 2 schizophrenia study.

Schizophrenia Treatment | 04/07/2026 | By News Bureau |  203

Saptalis Launches Cyclosporine Ophthalmic Emulsion

Saptalis Pharmaceuticals has launched Cyclosporine Ophthalmic Emulsion 0.05 percent in 30- and 60-count single-use vials, expanding its ophthalmology portfolio and improving access to high-quality treatment options for patients.

Schizophrenia Treatment | 16/06/2026 | By News Bureau |  107

US FDA Approves CAPLYTA (lumateperone) sNDA for Schizophrenia Relapse Reduction

US Food and Drug Administration (FDA) approves CAPLYTA (lumateperone) sNDA for schizophrenia, showing a 63 percent reduction in relapse risk and 84 percent relapse-free patients over six months, with strong long-term safety and stability data.

Schizophrenia Treatment | 28/04/2026 | By News Bureau |  262

LB Pharmaceuticals Starts Phase 3 Trial for LB-102 in Schizophrenia

LB Pharmaceuticals initiates Phase 3 NOVA-2 trial of LB-102 for schizophrenia, enrolling ~460 patients to assess PANSS score, symptoms and safety, with topline results expected in 2H 2027.

Schizophrenia Treatment | 26/03/2026 | By News Bureau |  279

FDA Approves Vanda Pharmaceuticals' BYSANTI as First-Line Therapy for Bipolar I Disorder and Schizophrenia

BYSANTI (milsaperidone), a new atypical antipsychotic from Vanda Pharmaceuticals, gains FDA approval for acute manic or mixed episodes in bipolar I disorder and schizophrenia in adults, with US launch planned for Q3 2026.

Schizophrenia Treatment | 21/02/2026 | By News Bureau |  412

Newron Pharmaceuticals Secures Euro 38 Million to Advance Phase III Schizophrenia Programme

Newron Pharmaceuticals strengthens its funding base with a multi-tranche equity raise to support late-stage development of evenamide in treatment-resistant schizophrenia.

Schizophrenia Treatment | 17/02/2026 | By News Bureau |  195